Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
HRF Double Nickase Plasmid (h): sc-402606-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HRF Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- HRF Double Nickase Plasmid (h) and HRF Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting TPT1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HRF Antibody (B-3): sc-133131
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HRF Double Nickase Plasmid (h) | sc-402606-NIC | 20 µg | $410.00 | |||
HRF Double Nickase Plasmid (h2) | sc-402606-NIC-2 | 20 µg | $410.00 |
Human TPT1 encodes histamine-releasing factor (HRF), a highly conserved cytosolic protein implicated in cell growth, stress adaptation, and survival signaling. HRF participates in processes linked to translational control and proteostasis, and has been associated with modulation of apoptosis and cellular responses to oxidative and inflammatory cues. Altered TPT1/HRF expression has been reported across diverse disease contexts, including cancer biology and immune-mediated inflammation, where it can correlate with proliferation, migration, and cytokine-associated phenotypes. These properties make TPT1 a useful target for dissecting pathways governing cell fate decisions, stress-response networks, and immune-relevant signaling in human model systems.
HRF Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the TPT1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within TPT1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt TPT1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of TPT1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.